Labcorp Holdings Inc. $LH Shares Bought by Lido Advisors LLC

Lido Advisors LLC boosted its stake in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 365.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,673 shares of the medical research company’s stock after acquiring an additional 3,668 shares during the quarter. Lido Advisors LLC’s holdings in Labcorp were worth $1,440,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new stake in Labcorp in the second quarter valued at approximately $7,792,000. Tidal Investments LLC boosted its stake in shares of Labcorp by 12.4% during the second quarter. Tidal Investments LLC now owns 30,559 shares of the medical research company’s stock valued at $8,557,000 after purchasing an additional 3,372 shares during the period. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Labcorp during the second quarter valued at approximately $168,222,000. AXQ Capital LP bought a new position in shares of Labcorp in the second quarter worth approximately $1,009,000. Finally, Royal Bank of Canada grew its holdings in shares of Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after purchasing an additional 133,549 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Labcorp

In other Labcorp news, EVP Brian J. Caveney sold 2,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president directly owned 34,562 shares in the company, valued at approximately $12,858,446.48. This represents a 5.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richelle P. Parham sold 1,078 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $361.22, for a total transaction of $389,395.16. Following the completion of the sale, the director directly owned 2,288 shares of the company’s stock, valued at approximately $826,471.36. This represents a 32.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,384 shares of company stock worth $1,241,707 over the last quarter. Corporate insiders own 0.84% of the company’s stock.

Labcorp Trading Up 0.1%

NYSE LH opened at $370.69 on Monday. Labcorp Holdings Inc. has a fifty-two week low of $245.00 and a fifty-two week high of $375.10. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. The stock has a 50 day simple moving average of $329.60 and a two-hundred day simple moving average of $292.58. The stock has a market cap of $30.10 billion, a P/E ratio of 30.41, a price-to-earnings-growth ratio of 2.09 and a beta of 0.86.

Labcorp (NYSE:LH – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $4.18 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, analysts forecast that Labcorp Holdings Inc. will post 18.51 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. Labcorp’s dividend payout ratio (DPR) is presently 23.63%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LH. Robert W. Baird lifted their target price on shares of Labcorp from $361.00 to $396.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Deutsche Bank reissued a “hold” rating and set a $355.00 price target on shares of Labcorp in a research report on Thursday, October 29th. Truist Financial raised their price target on shares of Labcorp from $365.00 to $395.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Mizuho set a $355.00 price objective on shares of Labcorp in a research report on Monday, August 10th. Finally, UBS Group boosted their price objective on shares of Labcorp from $380.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus price target of $369.08.

View Our Latest Report on Labcorp

Labcorp Company Profile

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Featured Stories

Institutional Ownership by Quarter for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.